Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer – A national survey performed at pathology departments in Sweden

References

• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244(4905)707–12
   PubMed Web of Science ®Google Scholar
• Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462–9
   PubMed Web of Science ®Google Scholar
• Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 2003; 9: 923–30
   PubMed Web of Science ®Google Scholar
• Schmidt M, Lewark B, Kohlschmidt N, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005; 7: R256–R266
   PubMed Web of Science ®Google Scholar
• Ryden L, Landberg G, Stal O, Nordenskjold B, Ferno M, Bendahl PO. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat 2008; 109: 351–7
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785)177–82
   PubMed Web of Science ®Google Scholar
• Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103–12
   PubMed Web of Science ®Google Scholar
• Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63–9
   PubMedGoogle Scholar
• Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005; 11: 6598–607
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265–74
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759–69
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007; 369(9555)29–36
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287–312
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18
   PubMed Web of Science ®Google Scholar
• Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467–72
   PubMed Web of Science ®Google Scholar
• Vocaturo A, Novelli F, Benevolo M, et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: A sensitive and practical method in the trastuzumab era. Oncologist 2006; 11: 878–86
   PubMed Web of Science ®Google Scholar
• Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972–7
   PubMed Web of Science ®Google Scholar
• Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 2003; 16: 173–82
   PubMed Web of Science ®Google Scholar
• Ellis IO, Bartlett J, Dowsett M, et al. Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233–7
   PubMed Web of Science ®Google Scholar
• http://www.nordiqc.org.
   Google Scholar
• Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24: 3032–8
   PubMed Web of Science ®Google Scholar
• Dowsett M, Hanna WM, Kockx M, et al. Standardization of HER2 testing: Results of an international proficiency-testing ring study. Mod Pathol 2007; 20: 584–91
   PubMed Web of Science ®Google Scholar
• http://www3.svls.se/sektioner/pa/.
   Google Scholar
• Altman D. Practical Statistics for Medical Research. Chapman & Hall, LondonUK 1991
   Google Scholar
• Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: An update from INQAT round III. Int J Biol Markers 2005;20:189–94.
   Web of Science ®Google Scholar
• Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing slide-based assays in breast cancer: Hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res 2007; 13: 2831–5
   PubMed Web of Science ®Google Scholar
• Paradiso A, Miller K, Marubini E, Pizzamiglio S, Verderio P. The need for a quality control of the whole process of immunohistochemistry human epidermal growth factor receptor 2/neu determination: A United Kingdom National External Quality Assessment Service/Italian Network for Quality Assessment of Tumor Biomarkers pilot experience. J Clin Oncol 2007; 25: e27–e28
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Andersson M, Christensen IJ, Moller S. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol 2008; 47: 784–8
   PubMed Web of Science ®Google Scholar